(Q38123074)

29 August 2017

title

A further TWEAK to multiple sclerosis pathophysiology (English)

1 reference

29 August 2017

1 reference

1 reference

Arash Nazeri

1

0 references

Pouria Heydarpour

object named as

Pouria Heydarpour

series ordinal

2

0 references

Mohammad Ali Sahraian

object named as

Mohammad Ali Sahraian

series ordinal

4

0 references

Amit Bar-or

series ordinal

6

object named as

Amit Bar-Or

1 reference

29 August 2017

3

Shokufeh Sadaghiani

1 reference

29 August 2017

Linda C Burkly

5

1 reference

29 August 2017

publication date

20 July 2013

1 reference

29 August 2017

published in

Molecular Neurobiology

1 reference

29 August 2017

volume

49

1 reference

29 August 2017

issue

1

1 reference

29 August 2017

page(s)

78-87

1 reference

Inflammatory cortical demyelination in early multiple sclerosis

29 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1007%2FS12035-013-8490-Y

The TWEAK/Fn14 pathway as an aggravating and perpetuating factor in inflammatory diseases: focus on inflammatory bowel diseases

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12035-013-8490-Y

TWEAK and Fn14. New players in the pathogenesis of atherosclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12035-013-8490-Y

TWEAK, a multifunctional cytokine in kidney injury

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12035-013-8490-Y

TWEAK and TRAF6 regulate skeletal muscle atrophy.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12035-013-8490-Y

TWEAK and Fn14: new molecular targets for cancer therapy?

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12035-013-8490-Y

TWEAK, a new secreted ligand in the tumor necrosis factor family that weakly induces apoptosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12035-013-8490-Y

TWEAK attenuates the transition from innate to adaptive immunity

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12035-013-8490-Y

TWEAK/Fn14 pathway: an immunological switch for shaping tissue responses

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12035-013-8490-Y

Involvement of TWEAK in interferon gamma-stimulated monocyte cytotoxicity

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12035-013-8490-Y

The TWEAK-Fn14 cytokine-receptor axis: discovery, biology and therapeutic targeting

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12035-013-8490-Y

Interactions of tumor necrosis factor (TNF) and TNF receptor family members in the mouse and human

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12035-013-8490-Y

A novel TNF receptor family member binds TWEAK and is implicated in angiogenesis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12035-013-8490-Y

TWEAKing tissue remodeling by a multifunctional cytokine: role of TWEAK/Fn14 pathway in health and disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12035-013-8490-Y

TWEAK, via its receptor Fn14, is a novel regulator of mesenchymal progenitor cells and skeletal muscle regeneration

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12035-013-8490-Y

TWEAK induces liver progenitor cell proliferation

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12035-013-8490-Y

TWEAK binding to the Fn14 cysteine-rich domain depends on charged residues located in both the A1 and D2 modules

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12035-013-8490-Y

TWEAK induces NF-kappaB2 p100 processing and long lasting NF-kappaB activation.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12035-013-8490-Y

A previously unrecognized protein-protein interaction between TWEAK and CD163: potential biological implications

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12035-013-8490-Y

Identification of the haemoglobin scavenger receptor.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12035-013-8490-Y

The CD163-expressing macrophages recognize and internalize TWEAK: potential consequences in atherosclerosis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12035-013-8490-Y

Studies of binding of tumor necrosis factor (TNF)-like weak inducer of apoptosis (TWEAK) to fibroblast growth factor inducible 14 (Fn14).

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12035-013-8490-Y

TWEAK and the central nervous system

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12035-013-8490-Y

Experimental autoimmune encephalomyelitis (EAE) as a model for multiple sclerosis (MS).

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12035-013-8490-Y

Anti-TWEAK monoclonal antibodies reduce immune cell infiltration in the central nervous system and severity of experimental autoimmune encephalomyelitis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12035-013-8490-Y

Targeting fibroblast growth factor-inducible-14 signaling protects from chronic relapsing experimental autoimmune encephalomyelitis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12035-013-8490-Y

The cuprizone animal model: new insights into an old story

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12035-013-8490-Y

TNF superfamily member TWEAK exacerbates inflammation and demyelination in the cuprizone-induced model

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12035-013-8490-Y

Fn14-TRAIL, a chimeric intercellular signal exchanger, attenuates experimental autoimmune encephalomyelitis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12035-013-8490-Y

Amelioration of autoimmune neuroinflammation by the fusion molecule Fn14·TRAIL

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12035-013-8490-Y

The TWEAK/Fn14 pathway in tissue remodeling: for better or for worse

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12035-013-8490-Y

Expression of TWEAK and its receptor Fn14 in the multiple sclerosis brain: implications for inflammatory tissue injury

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12035-013-8490-Y

Subpial demyelination in the cerebral cortex of multiple sclerosis patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12035-013-8490-Y

Cortical lesions in multiple sclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12035-013-8490-Y

Cortical demyelination in multiple sclerosis: a substrate for cognitive deficits?

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12035-013-8490-Y

Cortical demyelination and diffuse white matter injury in multiple sclerosis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12035-013-8490-Y

Pro-inflammatory effect of TWEAK/Fn14 interaction on human umbilical vein endothelial cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12035-013-8490-Y

TWEAK/Fn14 pathway modulates properties of a human microvascular endothelial cell model of blood brain barrier

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12035-013-8490-Y

Metalloproteinases in biology and pathology of the nervous system.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12035-013-8490-Y

Metalloproteinases: mediators of pathology and regeneration in the CNS.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12035-013-8490-Y

Serum gelatinase B, TIMP-1 and TIMP-2 levels in multiple sclerosis. A longitudinal clinical and MRI study

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12035-013-8490-Y

Matrix metalloproteinase-9 (MMP-9) and tissue inhibitor of matrix metalloproteinase (TIMP-1) in patients with relapsing-remitting multiple sclerosis treated with interferon beta

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12035-013-8490-Y

Elevated matrix metalloproteinase-9 and degradation of perineuronal nets in cerebrocortical multiple sclerosis plaques

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12035-013-8490-Y

Enhanced expression of MMP-7 and MMP-9 in demyelinating multiple sclerosis lesions

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12035-013-8490-Y

Resistance of young gelatinase B-deficient mice to experimental autoimmune encephalomyelitis and necrotizing tail lesions.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12035-013-8490-Y

TWEAK can induce pro-inflammatory cytokines and matrix metalloproteinase-9 in macrophages

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12035-013-8490-Y

Tumor necrosis factor-like weak inducer of apoptosis increases the permeability of the neurovascular unit through nuclear factor-kappa B pathway activation.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12035-013-8490-Y

TWEAK-Fn14 pathway inhibition protects the integrity of the neurovascular unit during cerebral ischemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12035-013-8490-Y

Tumor necrosis factor-related weak inducer of apoptosis augments matrix metalloproteinase 9 (MMP-9) production in skeletal muscle through the activation of nuclear factor-kappaB-inducing kinase and p38 mitogen-activated protein kinase: a potential r

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12035-013-8490-Y

How factors secreted from astrocytes impact myelin repair

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12035-013-8490-Y

Astrocytes--friends or foes in multiple sclerosis?

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12035-013-8490-Y

Astrocytes in multiple sclerosis: a product of their environment

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12035-013-8490-Y

Genomic analysis of reactive astrogliosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12035-013-8490-Y

Death receptor signalling in central nervous system inflammation and demyelination

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12035-013-8490-Y

Tumor necrosis factor-like weak inducer of apoptosis and fibroblast growth factor-inducible 14 mediate cerebral ischemia-induced poly(ADP-ribose) polymerase-1 activation and neuronal death

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12035-013-8490-Y

Multiple pathways of TWEAK-induced cell death

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12035-013-8490-Y

Cytokine cooperation in renal tubular cell injury: the role of TWEAK.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12035-013-8490-Y

TWEAK causes myotube atrophy through coordinated activation of ubiquitin-proteasome system, autophagy, and caspases.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12035-013-8490-Y

Mediation of poly(ADP-ribose) polymerase-1-dependent cell death by apoptosis-inducing factor

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12035-013-8490-Y

Inhibitors of poly(ADP-ribose) polymerase-1 suppress transcriptional activation in lymphocytes and ameliorate autoimmune encephalomyelitis in rats

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12035-013-8490-Y

The therapeutic effects of PJ34 [N-(6-oxo-5,6-dihydrophenanthridin-2-yl)-N,N-dimethylacetamide.HCl], a selective inhibitor of poly(ADP-ribose) polymerase, in experimental allergic encephalomyelitis are associated with immunomodulation.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12035-013-8490-Y

Toll-like receptor 2 and poly(ADP-ribose) polymerase 1 promote central nervous system neuroinflammation in progressive EAE.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12035-013-8490-Y

The cytokine tumor necrosis factor-like weak inducer of apoptosis and its receptor fibroblast growth factor-inducible 14 have a neuroprotective effect in the central nervous system

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12035-013-8490-Y

Increased MRI activity and immune activation in two multiple sclerosis patients treated with the monoclonal anti-tumor necrosis factor antibody cA2.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12035-013-8490-Y

Role of TWEAK in lupus nephritis: a bench-to-bedside review

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12035-013-8490-Y

A soluble Fn14-Fc decoy receptor reduces infarct volume in a murine model of cerebral ischemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12035-013-8490-Y

Serum MMP-9/TIMP-1 and MMP-2/TIMP-2 ratios in multiple sclerosis: relationships with different magnetic resonance imaging measures of disease activity during IFN-beta-1a treatment

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12035-013-8490-Y

TWEAK/Fn14 promotes apoptosis of human endometrial cancer cells via caspase pathway

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12035-013-8490-Y

Tumor Necrosis Factor-Like Weak Inducer of Apoptosis-Induced Neurodegeneration

21 January 2018

1 reference

12 December 2020

Involvement of TNF-like weak inducer of apoptosis in the pathogenesis of collagen-induced arthritis

1 reference

12 December 2020

TWEAK is expressed at the cell surface of monocytes during multiple sclerosis

1 reference

12 December 2020

TNF neutralization in MS: results of a randomized, placebo-controlled multicenter study. The Lenercept Multiple Sclerosis Study Group and The University of British Columbia MS/MRI Analysis Group

1 reference

12 December 2020

1 reference

12 December 2020

TWEAK stimulation of astrocytes and the proinflammatory consequences

1 reference

12 December 2020

PARP-1 inhibition prevents CNS migration of dendritic cells during EAE, suppressing the encephalitogenic response and relapse severity

1 reference

12 December 2020

Tumor necrosis factor-like weak inducer of apoptosis induces astrocyte proliferation through the activation of transforming-growth factor-α/epidermal growth factor receptor signaling pathway

1 reference

12 December 2020

Meningeal B-cell follicles in secondary progressive multiple sclerosis associate with early onset of disease and severe cortical pathology.

1 reference

12 December 2020

TWEAK is expressed by glial cells, induces astrocyte proliferation and increases EAE severity

1 reference

12 December 2020

TWEAK is a novel arthritogenic mediator

1 reference

12 December 2020

10.1007/S12035-013-8490-Y

Identifiers

DOI

1 reference

Dimensions Publication ID

29 August 2017

1040721658

0 references

1 reference